October 1, 2026 by Mohr Marketing
More inquiries do not necessarily mean more viable plaintiffs. Learning how to find plaintiffs for mass tort cases starts with a precise claimant...
September 30, 2026 by Mohr Marketing
A high count of ozempic lawsuit leads can look like momentum, but volume alone doesn’t show whether inquiries match a firm’s current criteria,...
September 28, 2026 by Mohr Marketing
More claimant inquiries do not automatically create a stronger NEC campaign. Effective NEC baby formula case acquisition depends on written screening...
September 27, 2026 by Mohr Marketing
A high lead count can still produce a weak pipeline. The value of roundup weedkiller cancer lawsuit leads depends on whether your team can review...
September 19, 2026 by Mohr Marketing
High-volume lead generation is a liability, not an asset. If your firm is drowning in unqualified inquiries while your marketing spend vanishes into...
September 15, 2026 by Mohr Marketing
The global tampon market is estimated at $7.25 billion in 2026, yet a landmark University of California, Berkeley study revealed sixteen heavy...
August 31, 2026 by Mohr Marketing
Why is your firm still racing four other competitors to reach the same claimant when you could be the only voice in the room? You’ve likely felt the...
August 29, 2026 by Mohr Marketing
Only 17% of qualified leads currently convert into signed retainers, leaving the vast majority of advertising spend on the cutting room floor. You...
August 27, 2026 by Mohr Marketing
Scaling a law firm on raw lead volume is a strategic failure that leads to wasted capital. You've likely experienced the frustration of high-intent...
August 26, 2026 by Mohr Marketing
In high-stakes litigation, your mass tort intake process is either a profit center or a massive financial leak. There's no middle ground. If your...